Rates of infectious keratitis and other ocular surface adverse events in corneal cross-linking for keratoconus and corneal ectasias performed in an office-based setting: a retrospective cohort study
- PMID: 37653457
- PMCID: PMC10472555
- DOI: 10.1186/s40662-023-00354-1
Rates of infectious keratitis and other ocular surface adverse events in corneal cross-linking for keratoconus and corneal ectasias performed in an office-based setting: a retrospective cohort study
Erratum in
-
Correction: Rates of infectious keratitis and other ocular surface adverse events in corneal cross-linking for keratoconus and corneal ectasias performed in an office-based setting: a retrospective cohort study.Eye Vis (Lond). 2023 Sep 25;10(1):41. doi: 10.1186/s40662-023-00360-3. Eye Vis (Lond). 2023. PMID: 37743491 Free PMC article. No abstract available.
Abstract
Background: This study aimed to compare the complication rates of epithelium-off corneal cross-linking (epi-off CXL) performed in an office-based setting with those of epi-off CXL performed in an operating room.
Methods: A retrospective cohort study, comprising 501 consecutive epi-off CXL procedures, performed in a non-sterile procedure room without laminar flow ventilation at the ELZA Institute in Zurich, Switzerland, between November 2015 and October 2021, was conducted.
Results: No cases of postoperative infectious keratitis were observed, while sterile infiltrates occurred in 10 out of 501 (2.00%) patients, all of whom responded well to topical steroid therapy. Delayed epithelialization (> 7 days) occurred in 14 out of 501 (2.79%) patients. No other adverse events were noted.
Conclusions: Office-based epi-off CXL does not appear to be associated with an increased risk of complications when compared to operating room settings.
Keywords: Cornea; Corneal cross-linking; Epithelium-off; Infectious keratitis; Keratoconus; Office-based; Slit lamp; Sterile infiltrates.
© 2023. The Author(s).
Conflict of interest statement
NH is CEO of EMAGine AG, a company producing a CXL device. FH holds a patent on a UV light source (PCT/CH 2012/000090) and is CSO of EMAGine AG. FH is an editorial board member of Eye and Vision. The other authors have no proprietary or commercial interest in any of the materials discussed in this article.
Similar articles
-
[Assessment of postoperative pain after corneal collagen cross-linking by iontophoresis vs the rapid epithelium-off technique in progressive keratoconus patients].J Fr Ophtalmol. 2015 Dec;38(10):904-11. doi: 10.1016/j.jfo.2015.05.006. Epub 2015 Nov 2. J Fr Ophtalmol. 2015. PMID: 26542679 French.
-
Sterile corneal infiltrates after corneal collagen cross-linking: evaluation of risk factors.Acta Ophthalmol. 2017 Mar;95(2):199-204. doi: 10.1111/aos.13218. Epub 2016 Oct 24. Acta Ophthalmol. 2017. PMID: 27775234
-
Transepithelial versus epithelium-off corneal cross-linking for the treatment of progressive keratoconus: a randomized controlled trial.Am J Ophthalmol. 2015 May;159(5):821-8.e3. doi: 10.1016/j.ajo.2015.02.005. Epub 2015 Feb 19. Am J Ophthalmol. 2015. PMID: 25703475 Clinical Trial.
-
Transepithelial versus epithelium-off corneal crosslinking for progressive keratoconus.Cochrane Database Syst Rev. 2021 Mar 23;3(3):CD013512. doi: 10.1002/14651858.CD013512.pub2. Cochrane Database Syst Rev. 2021. PMID: 33765359 Free PMC article.
-
Expanding indications for corneal cross-linking.Curr Opin Ophthalmol. 2023 Jul 1;34(4):339-347. doi: 10.1097/ICU.0000000000000967. Epub 2023 Apr 25. Curr Opin Ophthalmol. 2023. PMID: 37097193 Review.
References
-
- Kumar V, Lockerbie O, Keil SD, Ruane PH, Platz MS, Martin CB, et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol. 2004;80:15–21. - PubMed
LinkOut - more resources
Full Text Sources